Dublin, May 19, 2026 (GLOBE NEWSWIRE) -- The "Ophthalmics Collaboration and Licensing Deals 2019-2026" report has been added to ResearchAndMarkets.com's offering.

The definitive benchmark for ophthalmics dealmaking

Ophthalmics partnering spans a range of chronic and vision-threatening conditions, with deal structures reflecting specialised delivery methods, targeted therapies, and distinct clinical development pathways.

This report provides a comprehensive and structured analysis of 374 ophthalmics collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how ophthalmics deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by stage, asset type, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a specialised and innovation-driven therapeutic landscape
Full visibility into deal structure and execution

Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections

This level of transparency is critical to understanding how value, risk, and control are allocated within ophthalmics partnerships, particularly in areas requiring specialised delivery and long-term treatment approaches.

Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark live transactions
Prepare for negotiations with well-defined market context
Evaluate partnership opportunities and counterparties
Support internal strategy with robust, defensible data

What's included?

374 ophthalmics collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, therapy, and technology)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for ophthalmics dealmaking

Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how ophthalmics partnerships are structured, negotiated, and valued.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in ophthalmics dealmaking
2.1. Introduction
2.2. Ophthalmics partnering over the years
2.3. Ophthalmics partnering by deal type
2.4. Ophthalmics partnering by industry sector
2.5. Ophthalmics partnering by stage of development
2.6. Ophthalmics partnering by technology type
2.7. Ophthalmics partnering by therapeutic indication

Chapter 3 - Financial deal terms for ophthalmics partnering
3.1. Introduction
3.2. Disclosed financials terms for ophthalmics partnering
3.3. Ophthalmics partnering headline values
3.4. Ophthalmics deal upfront payments
3.5. Ophthalmics deal milestone payments
3.6. Ophthalmics royalty rates

Chapter 4 - Leading ophthalmics deals and dealmakers
4.1. Introduction
4.2. Most active in ophthalmics partnering
4.3. List of most active dealmakers in ophthalmics
4.4. Top ophthalmics deals by value

Chapter 5 - Ophthalmics contract document directory
5.1. Introduction
5.2. Ophthalmics partnering deals where contract document available

Chapter 6 - Ophthalmics dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by ophthalmics therapeutic target

Deal directory

Deal directory - Ophthalmics deals by company A-Z
Deal directory - Ophthalmics deals by technology type
Deal type definitions

Companies Featured

3SBio
4D Molecular Therapeutics
4P-Pharma
A*STAR Agency for Science
Technology and Research
AAVnerGene
ABB Optical Group
Abbvie
AbCellera Biologics
Abeona Therapeutics
Abpro
ABVC BioPharma
Accure Therapeutics
ACE Solutech
ActualEyes
Acucela
Adalvo
Adaptive Phage Therapeutics
Advanz Pharma
Aequus Pharmaceuticals
Aerie Pharmaceuticals
AEYE Health
AffaMed Therapeutics
Affilogic
AimMax Therapeutics
AJU Pharma
Aker BioMarine
Alcon Laboratories
Aldeyra Therapeutics
Alexion Pharmaceuticals
Alimera Sciences
Alnylam Pharmaceuticals
Alvotech
Ambiopharm
American Diabetes Association
AmerisourceBergen
Angios
Apellis Pharmaceuticals
Apexian Pharmaceuticals
Apotex
Applied Genetic Technologies
Arctic Vision
Ascidian Therapeutics
Asimov
Astellas Pharma
Atsena Therapeutics
Attillaps Holdings
Aura Biosciences
Aurolab
Avanzanite Bioscience
Avellino Labs
Avista Therapeutics
Axantia
AXIM Biotechnologies
Axovia Therapeutics
AyoxxA Biosystems
Bascom Palmer Eye Institute
Bausch & Lomb
Bausch Health Companies
Baxter International
Bayer
Beacon Therapeutics
Beam Therapeutics
Betta Pharmaceuticals
Beyeonics Vision
BHVI
Bio-Techne
BioCryst Pharmaceuticals
Bioeq IP
Biogen
BioLight
BioStem Technologies
Blackrock Neurotech
Blueprint Genetics
BlueRock Therapeutics
Boehringer Ingelheim
Bridge Biotherapeutics
Brigham and Women's Hospital
BVI Medical
C-Bridge Capital
California Institute for Regenerative Medicine
Capsida Biotherapeutics
Carl Zeiss
Carl Zeiss Meditec
Case Western Reserve University
Catalent
Catalyst Biosciences
CDR-Life
Celanese
Cella Therapeutics
Cell Cure Neurosciences
Cellusion
Celregen
Cerevast Therapeutics
Changchun High & New Technology Industries
Character Biosciences
Chiesi Farmaceutici
Children's Hospital Los Angeles
Children's Medical Research Institute
China Grand Pharmaceutical
China Medical System
Choroideremia Research Foundation
Cipla
City Therapeutics
Clarion Medical Technologies
ClearPoint Neuro
Clearside Biomedical
Clover Therapeutics
Coave Therapeutics
Coherus Biosciences
Columbia University
Combangio
Copernicus Therapeutics
Cortigent
Covenant Surgical Partners
Cristalia
CROMA Pharma
CS Pharmaceuticals
Curacle
CureVac
Cyagen Biosciences
Daiichi Sankyo
DAVI II Farmaceutica
De La Pena Eye Clinic
DelSiTech
Dermira
Diamond Pharma Services
Diana Davis Spencer Foundation
Digital Diagnostics
Diopsys
doc.ai
DotBio
Dr. Agarwal's Eye Hospitals
Dr. Reddy's Laboratories
Duke University
Dyno Therapeutics
Eastman Chemical Company
ECM Therapeutics
Eli Lilly
Eluminex Biosciences
Epimune Diagnostics
Equinox Science
ERS Genomics
eSight
Eton Pharmaceuticals
European Organization for Research and Treatment of Cancer
Everads Therapy
Eversight
Evommune
Evotec
Exonate
EyeCRO
Eyedetec Medical
Eyenovia
EyePoint Pharmaceuticals
Eyevensys
Famy Life Sciences
Fibrogen
Find Therapeutics
Florida Pharmaceutical Products
Forge Biologics
Formosa Pharmaceuticals
Formycon
ForSeeCon Eye Corporation
Foundation Fighting Blindness
FUJIFILM Cellular Dynamics
Galimedix Therapeutics
GC Biopharma
GelMEDIX
Gemini Therapeutics
Genentech
Genosity
Gensci
Gensight Biologics
Gentex
Glaucoma Research Foundation
Glaukos
Grifols
Gyroscope Therapeutics
Halozyme Therapeutics
HanAll Biopharma
HanchorBio
Harrow Health
Harvard Medical School
HealPros
Hemera Biosciences
Hemostemix
Henlius Biotech
Hopstem Biotechnology
Horama
Horizon Discovery
Horizon Europe
Horizon Therapeutics
Hovione
I-MED Pharma
IACTA Pharmaceuticals
Ichor Life Sciences
Ikarovec
Immervision
Immunocore
ImPact Biotech
Indoco
Inflammasome Therapeutics
InformedDNA
InMed Pharmaceuticals
Intas Pharmaceuticals
Intellia Therapeutics
Intratus
Iolyx Therapeutics
IQVIA
IRIS
IRIS International
Israeli National Authority for Technological Innovation
iSTAR Medical
Itrom Pharmaceutical Group
Ivantis
iVeena Delivery Systems
Iveric Bio
Jaeb Center for Health Research Foundation
Janssen Pharmaceuticals
Janssen Research & Development
jCyte
Ji Xing Pharmaceuticals
Johns Hopkins University
Johnson & Johnson Vision
Joslin Diabetes Center
K2M
Kanaph Therapeutics
Kane Biotech
Kemwell BioPharma
Kiora Pharmaceuticals
Kissei Pharmaceutical
Klinge Biopharma
Kodiak Sciences
Konkuk University
Kowa
Kriya Therapeutics
Kubota Vision
Kuria Therapeutics
Kwangdong Pharmaceutical
Laboratoires Thea
LABORATORIOS SAVAL
Lansheng Medical
Lantheus Holding
Launch Therapeutics
Lee's Pharmaceutical
Leiden University
LENZ Therapeutics
LGC
LianBio
Lineage Cell Therapeutics
LION Eye Group
LLamasoft
Lochan
Locus Biosciences
Lotus Pharmaceuticals
LumiThera
Lunatus
Maastricht University
Magruder Eye Institute
Mannin Research
Marchon Eyewear
Massachusetts Eye and Ear Infirmary
Mawson Infrastructure
Max-Planck
Mayo Clinic
McMaster University
mCureX Therapeutics
Medical Food Solutions Research
Medical University of South Carolina
Medvisis
MeiraGTx
MellingMedical
Melt Pharmaceuticals
Menicon
Minnetronix
miRagen Therapeutics
MitoChem Therapeutics
Mitsubishi Tanabe Pharma
Mosaic Biosciences
Mundipharma
MyMD Pharmaceuticals
Nanomerics
Nanoscope Therapeutics
Narayana Nethralaya Foundation
NASA
National Cancer Institute
National Eye Institute
National Institutes of Health
National Organization for Rare Disorders
National University of Singapore
Neuraly
Neurolens
Neurophth Therapeutics
Nevakar
NextPharma
NGM Biopharmaceuticals
Nicox
Nippon Shinyaku
Nona Biosciences
Northway Biotechpharma
NovaBay Pharmaceuticals
Novaliq
Novartis
Novelty Nobility
Noveome Biotherapeutics
Novotech
NTC
Numab
Ocugen
Ocular Therapeutics
Ocular Therapeutix
Oculis
Oculogenex
Ocumension Therapeutics
Ocuphire Pharma
Odylia Therapeutics
OKKO Health
OKYO Pharma
OliX Pharmaceuticals
Olympic Ophthalmics
Omega Therapeutics
Omeros
ONL Therapeutics
OphtAI
Ophthotech
Opsis Therapeutics
Opthea
Optifye Therapeutics
Optina Diagnostics
Optomed
Opus Genetics
Ora
Orbis
Orbit Biomedical
Osmotica Pharmaceuticals
Otsuka
Outlook Therapeutics
Oxford BioMedica
Oyster Point Pharma
Palatin Technologies
PanOptica
Perelman School of Medicine
PharmAbcine
Pharmaleads
Phillips-Medisize
Pieris Pharmaceuticals
Pierre Fabre
Ping An Ventures
Plex Pharmaceuticals
Polifarma
PolyPhotonix
PreCerv
Precise Biometrics
Precision Optics
Prevail InfoWorks
Promedica International
ProQR Therapeutics
ProtoKinetix
Provectus Biopharmaceuticals
PTC Therapeutics
Q BioMed
Quest Diagnostics
Quotient
Rallybio
Rayner Surgical
Ray Therapeutics
Re-Vana Therapeutics
RecensMedical
Regeneron Pharmaceuticals
Regenerx
Regenxbio
RemeGen
Remidio Innovative Solutions
Rentschler Biotechnologie
Resilience
Retinagenix
RetinAI Medical
RetinalGeniX Technologies
RetiSpec
ReVision Optics
Revision Skincare
Revolo Biotherapeutics
RevOpsis Therapeutics
Ribomic
Ripple Therapeutics
Roche
RTW Investments
RVL Pharmaceuticals
RxCell
Rxilient Biotech
Saban Research Institute of Children's Hospital Los Angeles
SAMIL Pharmiceuticals
Samsara Vision
Samsung Bioepis
Samsung Biologics
SanBio
Sanofi
Santen
Santen Pharmaceutical
Santhera Pharmaceuticals
SATT Conectus Alsace
Schepens Eye Research Institute
Scohia Pharma
Second Sight Medical
Seer
Selagine
SemaThera
Senju Pharmaceutical
Senti Biosciences
SGN Nanopharma
Shandong Boan Biological Technology
Shape Therapeutics
SIFI (Societa Industria Farmaceutica Italiana)
Sight Sciences
Singapore Eye Research Institute (SERI)
Sintetica
SipNose
SiSaf
Skye Bioscience
Slayback Pharma
Societal CDMO
Sonoma Pharmaceuticals
SparingVision
Spark Therapeutics
SpliceBio
STADA Arzneimittel
Stanford University
Stanford University School of Medicine
State University of New York
StemSight
Stuart Therapeutics
Sun Pharma Advanced Research Company
Sun Pharmaceutical
Surrozen
SwissLens
Sydnexis
Tabuk Pharmaceuticals
Taiwan Liposome Company
TALLC
Tangible Science
Taro Pharmaceuticals
Tarsius Pharma
Tarsus Pharmaceuticals
TeamedOn International
TearLab
Technological University Dublin
Teva Pharmaceutical Industries
Thea Open Innovation
ThinkCyte
Tianjin CanSino Biotechnology
Titan Pharmaceuticals
Toolgen
Topcon
Translational Research Institute for Space Health
Trethera
Tufts Medical Center
Tufts University
Turn Biotechnologies
UCB
Undisclosed Company
Uni-Bio Science
University of British Columbia
University of California Los Angeles
University of Colorado
University of Florida Research Foundation
University of Hong Kong
University of Massachusetts Medical School
University of Miami
University of Minnesota
University of Nebraska
University of Pennsylvania
University of Pennsylvania School of Veterinary Medicine
University of Pittsburgh
Usher Syndrome Coalition
ValenzaBio
Verana Health
Versea Ophthalmics
Vial
Viatris
Viela Bio
ViGeneron
Viralgen
Viridian Therapeutics
Vision Care Group
Vision Essence
Vision Institute
VisionWeb
Visiox Pharma
Visus Therapeutics
Vivani Medical
VivaVision Biotech
Vivior
Vizient
VSP Optics
Vyluma
Wagner Macula Retina Center
Wakamoto Pharmaceutical
Wake Forest University
Wallace H. Coulter Foundation
WuXi Advanced Therapies
Xbrane Biopharma
Xencor
Xequel Bio
XERIS Pharmaceuticals
Yangtze River Pharmaceutical Group
Yarrow Bioscience
Ypsomed
Zhaoke (Hong Kong) Ophthalmology Pharmaceutical
Zhonglan Electronic Technology
ZipBio

For more information about this report visit https://www.researchandmarkets.com/r/5c5wuy

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900

Ophthalmics Collaboration and Licensing Agreements Benchmark Report 2026: Structured Analysis of 374 Deals - Upfronts, Milestones, and Royalty Structures